Jan 29, 2009 - Alexion Pharmaceuticals, Inc., today announced that Canada's national healthcare regulatory agency, Health Canada, has approved the use of Soliris (eculizumab) for the treatment of all patients in Canada with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Canada for the treatment of PNH.
The details can be read here.
No comments:
Post a Comment